Head-to-head · WeighScore
Edessa vs June Health
The verdict
Edessa takes it — 70.8/100 to 63/100.
Edessa grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Clean three-rung tables one click in, behind a homepage whose three cards all quote six-month rungs and whose cheapest belongs to a different drug.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Edessa | June Health |
|---|---|---|
| WeighScore | 70.8/100 | 63/100 |
| Grade | C | C |
| Scorecard rank | #115 | #287 |
| Semaglutide | $179/mo month-to-month injectable ($135 only on a 6-month prepay) | $179/mo (starting dose, compounded) |
| Tirzepatide | $239/mo month-to-month ($209 only on a 6-month prepay) | $179/mo (starting dose, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
Graded #115 · C
Strengths
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
- All-inclusive: provider consultation, medication, free expedited shipping, ongoing check-ins and 24/7 clinical support, and HSA and FSA eligible
- An oral tablet sits beside the two injections
Where it loses points
- The homepage leads with "Start for just $135", a six-month prepay on the semaglutide injection; month-to-month tirzepatide is $239
- All three homepage cards quote the six-month rung, so the real monthly rates appear only after a click
- Its Terms give two corporate forms for the same company in one clause — "Edessa Group, LLC, a Nevada corporation"
- "Join 100,000+ successful GLP-1 patients" carries no source, and the money-back guarantee's terms are on no marketing page
- No lab or monitoring protocol is published
Graded #287 · C
Strengths
- Offers both injectable and oral compounded semaglutide and tirzepatide
- Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
- Full per-dose price list published on-site with no signup required to view it
- Provider consult ('licensed clinician evaluation') is bundled into the displayed price
- Free discreet shipping advertised with 2-3 day delivery
Where it loses points
- No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
- No LegitScript seal or other pharmacy-verification badge found anywhere on the site
- Legal entity, prescribing medical group, and compounding pharmacy partner are not named
- Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
- Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.